Fintech, Real-time Big-Data Analytics Provider, Nowcast, Inc.

Ryota Hayashi

Fintech, Real-time Big-Data Analytics Provider

Nowcast, Inc.

We at Nowcast develop "Big-Data Economic Analytics Platforms".  We aim to revolutionize the financial markets by providing "accurate" and "real-time" analytics based on economic indicators and corporate activity data procured worldwide. 

Our Main Services

(1) Real-time Analytics
With our Nikkei CPI Now Index at our core, we provide real time analytics of global economic indicators such as POS Data. By utilizing Big-Data technology, we also provide real-time analytics of micro level data such as corporate earnings. 

(2) Big-Data Application Consulting
We too provide business consultation and conduct joint research on initiatives that strive to use data, such as from the operation capacity of construction machinery to number of passengers on railroad trains, as economic indicators. We provide continuous support to Data Scientists specialized in economics in their proposal stage, product development and up till its business development. 

(3) Monetary Policy Insights
With the proactive involvement of and support from from academicians in macroeconomics & key figures in the financial industry, we produce reports, conduct seminars and meetings that discuss about the forecast of financial markets, provide intellectual suggestions on asset allocation, etc. 

Macroeconomics

<ul class="ember-tether-target ember-tether-element-attached-top ember-tether-element-attached-left ember-tether-target-attached-top ember-tether-target-attached-right"><li>"Nikkei CPINow" is a statistical database produced by Nowcast Inc. that provides real-time economic statistics using so-called “big data” gathered on a real-time basis; making it possible to “nowcast” economic developments, that is, to gauge them almost in real time.</li><li>Nikkei CPINow was launched in January 2016, disseminating the new “CPINow” price indeces, which succeeds and improves upon the Nikkei UTokyo Daily Price Index.</li><li>This December 2016 Review looks into analyzing the current developments in Japan's economy based on The Nikkei CPINow S index &amp; T index.</li></ul>

"Nikkei CPINow" is a statistical database produced by Nowcast Inc. that provides real-time economic statistics using so-called “big data” gathered on a real-time basis; making it possible to “nowcast” economic developments, that is, to gauge them almost in real time.Nikkei CPINow was launched in January 2016, disseminating the new “CPINow” price indeces, which succeeds and improves upon the Nikkei UTokyo Daily Price Index.This December 2016 Review looks into analyzing the current developments in Japan's economy based on The Nikkei CPINow S index &amp; T index.

December 2016 Review of Current Developments in Japan's Economy

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/5873" target="_blank" data-smartkarma-citation="entities:5873:1">Nihon Chouzai Co Ltd (3341 JP)</a> common stock could have potential 122% upside (DCF). Using sum-of-parts DCF method, we calculated the fair value of the common stock= Yen 9,520. The company's origins lie in the dispensing pharmacies. While the company has a major Japanese market share in this business, it seems to have matured. On the other hand, the company has successfully diversified into the high-margin generic drugs business which seems to be benefiting from the Japanese government's target to shift towards increased generic drug use to save health-care costs. The company also has 1.2% dividend yield.The company's ROE (22.6%) is higher than the industry average. ROIC (9.98%) is higher than the cost of capital and we expect it to further increase over next 5 years due to increased revenue contribution from generic drugs business. The company's EV/EBITDA (10.35) is also lower than the industry average and the forward EV/EBITDA ratio for FY2018 (5.10) and FY2019 (4.73) also reflect that the common stock could have upside from its current level.

Nihon Chouzai Co Ltd (3341 JP) common stock could have potential 122% upside (DCF). Using sum-of-parts DCF method, we calculated the fair value of the common stock= Yen 9,520. The company's origins lie in the dispensing pharmacies. While the company has a major Japanese market share in this business, it seems to have matured. On the other hand, the company has successfully diversified into the high-margin generic drugs business which seems to be benefiting from the Japanese government's target to shift towards increased generic drug use to save health-care costs. The company also has 1.2% dividend yield.The company's ROE (22.6%) is higher than the industry average. ROIC (9.98%) is higher than the cost of capital and we expect it to further increase over next 5 years due to increased revenue contribution from generic drugs business. The company's EV/EBITDA (10.35) is also lower than the industry average and the forward EV/EBITDA ratio for FY2018 (5.10) and FY2019 (4.73) also reflect that the common stock could have upside from its current level. 

Nihon Chouzai: 3331JP:Diversifying from Dispensing Pharmacies to High-Margin Generic Drugs Business.

Japan

NIHON CHOUZAI Co., Ltd. operates a drug store chain in Japan.  The Company manages drug prescriptions, orders, and inventories of all stores through an online system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nihon Chouzai (3341 JP)

December 2016 Review of Current Developments in Japan's Economy

"Nikkei CPINow" is a statistical database produced by Nowcast Inc. that provides real-time economic statistics using so-called “big data”...

Nowcast, Inc.

Nihon Chouzai: 3331JP:Diversifying from Dispensing Pharmacies to High-Margin Generic Drugs Business.

Nihon Chouzai Co Ltd (3341 JP) common stock could have potential 122% upside (DCF). Using sum-of-parts DCF method, we calculated the fair value of...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)